CRACW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• On November 10, 2025, we consummated our IPO of 17,250,000 Units at a price of $10.00 per Unit, generating gross proceeds of $172,500,000. Simultaneously with the closing of the IPO, we consummated the sale of 375,000 Private Placement Units at a price of $8.00 per Private Placement Unit (175,000 to…

• On March 30, 2026, we entered into the Business Combination Agreement with Merger Sub and Carvix. Subject to the terms and conditions of the Business Combination Agreement, we will effect a domestication to Delaware, and immediately thereafter Merger Sub will merge with and into Carvix, with Carvix …

• We expect to continue to incur significant costs in the pursuit of our Business Combination plans. We cannot assure you that our plans to complete a Business Combination will be successful.

• We have neither engaged in any principal operations nor generated any revenues to date. Our only activities since inception have been organizational activities, those necessary to prepare for the IPO, and, after the IPO, identifying a target company for a Business Combination, including the entry in…

• For the three months ended March 31, 2026, we had a net loss of $263,493, consisting of general and administrative costs of $68,837, professional fees of $115,000, and a loss on the change in fair value of warrant liability of $1,604,397, partially offset by dividends earned on marketable securities…

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a Business Combination will be successful.

• We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities and those necessary to prepare for this offering. Following this offering, we will not generate any operating revenues until after completion of our i…

• For the three months ended September 30, 2025, we had net income of $96, consisting of interest income. For the period from April 29, 2025 (inception) through September 30, 2025, we had net income of $149, consisting of interest income.

• Our liquidity needs have been satisfied prior to consummation of the Initial Public Offering through advances on behalf of the Company of $25,000 from the sale of the founder shares to our sponsor and less up to $5,000,000 in loans from our sponsor under an unsecured promissory note. As of September…

• Subsequent to the quarterly period covered by this Quarterly Report on Form 10-Q, on November 10, 2025, we consummated the Initial Public Offering of 17,250,000 Units, which includes the full exercise by the underwriter of its over-allotment option of 2,250,000 Units, at $10.00 per Unit, generating …

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2026, the end of the fiscal quarter covered by this…

• As previously disclosed in our Annual Report on Form 10-K for the period from April 29, 2025 (inception) through December 31, 2025, management identified a material weakness in our internal control over financial reporting in connection with the accounting for complex financial instruments — specifi…

• In response to the material weakness, we are continuing to enhance our internal control over financial reporting through (i) the engagement of external accounting and SEC reporting professionals with expertise in evaluating and accounting for complex financial instruments under U.S. GAAP, (ii) addit…

• Other than the remediation activities described above, there were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• Under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer (the “Certifying Officers”), we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in R…

• The Company is in the process of developing its internal control over financial reporting. During the quarter ended September 30, 2025, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, such controls. …